Stifel Financial Corp Invests $229,000 in Masimo Co. (NASDAQ:MASI)

Stifel Financial Corp purchased a new position in shares of Masimo Co. (NASDAQ:MASI) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 1,716 shares of the medical equipment provider’s stock, valued at approximately $229,000.

Several other large investors have also recently added to or reduced their stakes in the company. Centiva Capital LP purchased a new position in Masimo in the third quarter worth $678,000. Clearline Capital LP purchased a new position in shares of Masimo in the 3rd quarter valued at about $21,337,000. Erste Asset Management GmbH purchased a new position in shares of Masimo in the 3rd quarter valued at about $7,333,000. Edgestream Partners L.P. lifted its stake in shares of Masimo by 103.9% in the third quarter. Edgestream Partners L.P. now owns 10,449 shares of the medical equipment provider’s stock valued at $1,393,000 after purchasing an additional 5,325 shares during the period. Finally, Fred Alger Management LLC purchased a new stake in Masimo during the third quarter worth about $595,000. 85.96% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have issued reports on MASI shares. Raymond James increased their target price on shares of Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a report on Friday. Stifel Nicolaus reaffirmed a “buy” rating and issued a $190.00 price objective (up from $170.00) on shares of Masimo in a research note on Friday, November 22nd. Piper Sandler boosted their target price on Masimo from $180.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 18th. BTIG Research upped their target price on Masimo from $166.00 to $170.00 and gave the company a “buy” rating in a report on Monday, October 14th. Finally, Wells Fargo & Company lifted their price target on Masimo from $171.00 to $193.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, Masimo presently has an average rating of “Moderate Buy” and an average price target of $179.67.

Masimo Stock Performance

NASDAQ MASI opened at $170.97 on Monday. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. Masimo Co. has a fifty-two week low of $101.61 and a fifty-two week high of $180.97. The business has a fifty day moving average of $162.96 and a 200-day moving average of $136.32. The stock has a market cap of $9.15 billion, a price-to-earnings ratio of 117.91 and a beta of 1.01.

Masimo (NASDAQ:MASI) last announced its earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.14. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The firm had revenue of $504.60 million during the quarter, compared to the consensus estimate of $502.87 million. During the same quarter in the previous year, the company posted $0.63 EPS. The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. As a group, analysts predict that Masimo Co. will post 4.03 earnings per share for the current fiscal year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.